$TLIS
Talis Biomedical Corp Stock $tlis

$tlis Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024037648 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$73.00K	$195.0K	$2.134M
YoY Change	-94.01%	-24.12%	-55.65%
Cost Of Revenue	$6.000K	$8.000K	$41.00K
YoY Change	-70.0%	-99.66%	-99.51%
Gross Profit	$67.00K	$187.0K	$2.093M
YoY Change	-94.41%	-109.01%	-158.48%
Gross Profit Margin	91.78%	95.9%	98.08%
Selling, General & Admin	$11.65M	$6.602M	$28.21M
YoY Change	82.08%	-38.84%	-30.73%
% of Gross Profit	17389.55%	3530.48%	1348.02%
Research & Development	$2.533M	$8.041M	$40.69M
YoY Change	-81.64%	-47.24%	-42.55%
% of Gross Profit	3780.6%	4300.0%	1944.29%
Depreciation & Amortization	$262.0K	$211.0K	$770.0K
YoY Change	50.57%	-94.08%	-88.33%
% of Gross Profit	391.04%	112.83%	36.79%
Operating Expenses	$14.18M	$14.64M	$68.91M
YoY Change	-29.76%	-43.76%	-38.23%
Operating Profit	-$14.12M	-$14.46M	-$66.82M
YoY Change	-25.69%	-48.58%	-41.97%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$1.082M	$996.0K	$4.808M
YoY Change	-7.2%	-15.81%	126.05%
Pretax Income	-$13.04M	-$13.46M	-$62.01M
YoY Change	-26.9%	-50.02%	-45.13%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$13.04M	-$13.46M	-$62.01M
YoY Change	-26.9%	-50.02%	-45.13%
Net Earnings / Revenue	-17856.16%	-6902.56%	-2905.67%
Basic Earnings Per Share	-$7.15		-$34.12
Diluted Earnings Per Share	-$7.15	-$7.39	-$34.12
COMMON SHARES
Basic Shares Outstanding	31.69M	3.812M	1.818M
Diluted Shares Outstanding	1.822M		1.818M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$70.34M	$76.73M	$76.73M
YoY Change	-37.73%	-41.06%	-41.06%
Cash & Equivalents	$70.30M	$76.70M
Short-Term Investments
Other Short-Term Assets	$827.0K	$901.0K	$901.0K
YoY Change	-66.95%	-67.62%	-67.62%
Inventory
Prepaid Expenses
Receivables	$6.000K	$50.00K	$50.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$71.17M	$77.68M	$77.68M
YoY Change	-38.43%	-41.72%	-41.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.628M	$3.030M	$15.45M
YoY Change	-55.2%	-8.51%	-54.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.542M	$1.542M	$1.542M
YoY Change	0.0%	-13.18%	-13.18%
Total Long-Term Assets	$11.32M	$16.99M	$16.99M
YoY Change	-35.16%	-52.81%	-52.81%
TOTAL ASSETS
Total Short-Term Assets	$71.17M	$77.68M	$77.68M
Total Long-Term Assets	$11.32M	$16.99M	$16.99M
Total Assets	$82.49M	$94.67M	$94.67M
YoY Change	-38.0%	-44.08%	-44.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.619M	$1.339M	$1.339M
YoY Change	-6.51%	-64.46%	-64.46%
Accrued Expenses	$992.0K	$715.0K	$7.433M
YoY Change	-38.54%	-27.7%	-16.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.471M	$8.772M	$8.772M
YoY Change	-15.29%	-30.78%	-30.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$16.34M	$16.79M	$16.79M
YoY Change	39.07%	-43.82%	-43.82%
Total Long-Term Liabilities	$16.34M	$16.79M	$16.79M
YoY Change	39.07%	-43.82%	-43.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.471M	$8.772M	$8.772M
Total Long-Term Liabilities	$16.34M	$16.79M	$16.79M
Total Liabilities	$25.81M	$25.56M	$25.56M
YoY Change	12.56%	-39.94%	-39.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$553.0M	-$540.0M
YoY Change	11.54%	12.97%
Common Stock	$609.7M	$609.1M
YoY Change	0.62%	0.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$56.68M	$69.12M	$69.12M
YoY Change
Total Liabilities & Shareholders Equity	$82.49M	$94.67M	$94.67M
YoY Change	-38.0%	-44.08%	-44.08%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$13.04M	-$13.46M	-$62.01M
YoY Change	-26.9%	-50.02%	-45.13%
Depreciation, Depletion And Amortization	$262.0K	$211.0K	$770.0K
YoY Change	50.57%	-94.08%	-88.33%
Cash From Operating Activities	-$6.427M	-$11.36M	-$53.24M
YoY Change	-60.97%	-16.14%	-46.83%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$93.00K	$486.0K
YoY Change	-100.0%	-289.8%	-69.91%
Acquisitions
YoY Change
Other Investing Activities	$30.00K
YoY Change
Cash From Investing Activities	$30.00K	$93.00K	-$486.0K
YoY Change	-225.0%	-289.8%	-69.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.000K	0.000	33.00K
YoY Change	-93.94%		-91.87%
NET CHANGE
Cash From Operating Activities	-6.427M	-11.36M	-53.24M
Cash From Investing Activities	30.00K	93.00K	-486.0K
Cash From Financing Activities	2.000K	0.000	33.00K
Net Change In Cash	-6.395M	-11.26M	-53.69M
YoY Change	-61.14%	-17.13%	-47.02%
FREE CASH FLOW
Cash From Operating Activities	-$6.427M	-$11.36M	-$53.24M
Capital Expenditures	$0.00	-$93.00K	$486.0K
Free Cash Flow	-$6.427M	-$11.26M	-$53.73M
YoY Change	-61.02%	-17.13%	-47.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001584751
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration	http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember
CY2023	us-gaap	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense
CY2022	us-gaap	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40047
CY2023	dei	Entity Registrant Name EntityRegistrantName	Talis Biomedical Corporation
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3122255
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1375 West Fulton Market
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 700
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Chicago
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60607
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	433-3000
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	TLIS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	8151667000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31685660
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Chicago, Illinois
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76732000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130191000
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	50000
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	308000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	901000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2783000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	77683000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	133282000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3030000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3312000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12419000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30920000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1542000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1776000
CY2023Q4	us-gaap	Assets Assets	94674000
CY2022Q4	us-gaap	Assets Assets	169290000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1339000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3768000
CY2023Q4	tlis	Accrued Compensation Current AccruedCompensationCurrent	3836000
CY2022Q4	tlis	Accrued Compensation Current AccruedCompensationCurrent	4212000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	715000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	989000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2882000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3703000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8772000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12672000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16786000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29879000
CY2023Q4	us-gaap	Liabilities Liabilities	25558000
CY2022Q4	us-gaap	Liabilities Liabilities	42551000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1821986
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1821986
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1811396
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1811396
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	609074000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	604690000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-539961000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-477954000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	69116000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126739000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	94674000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	169290000
CY2023	us-gaap	Revenues Revenues	2134000
CY2022	us-gaap	Revenues Revenues	4812000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	41000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8391000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40694000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70831000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28214000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40729000
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	68949000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113012000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-34.12
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-34.12
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-62.77
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-62.77
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1817506
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1817506
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1800447
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	119951000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-66815000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-115139000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4808000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2127000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-62007000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1800447
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	233977000
CY2022	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	98000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	308000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5368000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113012000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126739000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	33000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4351000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	69116000
CY2023	us-gaap	Profit Loss ProfitLoss	-62007000
CY2022	us-gaap	Profit Loss ProfitLoss	-113012000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4351000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	5368000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	770000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8830000
CY2023	tlis	Noncash Lease Expense NoncashLeaseExpense	4304000
CY2022	tlis	Noncash Lease Expense NoncashLeaseExpense	2771000
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	2766000
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	3593000
CY2023	tlis	Increase Decrease In Grants Receivable IncreaseDecreaseInGrantsReceivable	-259000
CY2022	tlis	Increase Decrease In Grants Receivable IncreaseDecreaseInGrantsReceivable	125000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1879000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-604000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	741000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2429000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1194000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-3133000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-7712000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53240000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-100136000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	486000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1615000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-486000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1615000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	98000
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	33000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	308000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	406000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-53693000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-101345000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	131967000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	233312000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78274000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	131967000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	7265000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	19245000
CY2023	tlis	Remeasurement Of Operating Lease Right Of Use Asset For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModification	-18696000
CY2022	tlis	Remeasurement Of Operating Lease Right Of Use Asset For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModification	0
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76732000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130191000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1542000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1776000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78274000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	131967000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-62000000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76700000
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	1500000
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	a 1-for-15 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share, effective as of 5:00 p.m., Eastern Time, on July 5, 2023 (the “Reverse Stock Split”). On this date, every 15 issued and outstanding shares of common stock were converted into one share of common stock, with any fractional shares resulting from the Reverse Stock Split rounded up to the nearest whole share.
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions, including knowledge about current events and expectations about actions the Company may take in the future, that the Company believes are reasonable under the circumstances. Actual results could vary from the amounts derived from management’s estimates and assumptions.</span>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of credit risk and other risks and uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, and accounts receivables. The Company’s cash and restricted cash are deposited in accounts at large financial institutions and its cash equivalents are primarily held in prime and U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">government money market funds. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash, restricted cash</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and cash equivalents are held.</span></p>
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	2800000
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	3600000
CY2023	tlis	Accrued Charges AccruedCharges	3387000
CY2023	tlis	Accrued Cash Payments AccruedCashPayments	-1057000
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2330000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15974000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15150000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12944000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12822000
CY2023Q4	tlis	Property Plant And Equipment Before Construction Inprogress PropertyPlantAndEquipmentBeforeConstructionInprogress	3030000
CY2022Q4	tlis	Property Plant And Equipment Before Construction Inprogress PropertyPlantAndEquipmentBeforeConstructionInprogress	2328000
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	0
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	984000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3030000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3312000
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	0
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	tlis	Sales To Customers SalesToCustomers	0
CY2023	tlis	Remeasurement Of Operating Lease Right Of Use Asset For Lease Modification RemeasurementOfOperatingLeaseRightOfUseAssetForLeaseModification	-18700000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	6635000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	4100000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	787000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	834000
CY2023	us-gaap	Lease Cost LeaseCost	7422000
CY2022	us-gaap	Lease Cost LeaseCost	4934000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	3965000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1360000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.064
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2970000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3055000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3144000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3235000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3329000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	9177000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	24910000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5243000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	19667000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2882000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16786000
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one vote per share
CY2022Q3	tlis	Minimum Bid Price Requirement MinimumBidPriceRequirement	1
CY2022Q3	tlis	Trading Price TradingPrice	1
CY2023Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	As a result of the Reverse Stock Split, every 15 shares of common stock issued and outstanding were converted into one share of common stock with any fractional shares resulting from the Reverse Stock Split rounded up to the nearest whole share.
CY2023Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0
CY2023	tlis	Stockholders Equity Decreased Reverse Stock Split StockholdersEquityDecreasedReverseStockSplit	1-for-15
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	559542
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	52.87
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	318122
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.44
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	127117
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	21.83
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	32317
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	52.1
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	718230
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.28
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-62000000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113000000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	718230
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	38.28
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	281946
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	65.08
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y4M24D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M18D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P8Y3M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.731
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.713
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.036
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.029
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.05
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.78
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4351000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5368000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.07
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.023
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.009
CY2023	tlis	Effective Income Tax Rate Reconciliation Permanent Deterrence Percentage EffectiveIncomeTaxRateReconciliationPermanentDeterrencePercentage	-0.023
CY2022	tlis	Effective Income Tax Rate Reconciliation Permanent Deterrence Percentage EffectiveIncomeTaxRateReconciliationPermanentDeterrencePercentage	-0.005
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.28
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.274
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	81749000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	66709000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9749000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	8384000
CY2023Q4	tlis	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	5806000
CY2022Q4	tlis	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	9420000
CY2023Q4	tlis	Deferred Tax Assets Manufacturing Line And Production Equipment DeferredTaxAssetsManufacturingLineAndProductionEquipment	29413000
CY2022Q4	tlis	Deferred Tax Assets Manufacturing Line And Production Equipment DeferredTaxAssetsManufacturingLineAndProductionEquipment	27875000
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	12624000
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	12669000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3118000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	2838000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	20706000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	17880000
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	702000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1200000
CY2023Q4	tlis	Deferred Tax Assets Other Accruals DeferredTaxAssetsOtherAccruals	583000
CY2022Q4	tlis	Deferred Tax Assets Other Accruals DeferredTaxAssetsOtherAccruals	905000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	164450000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	147880000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	160784000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	140411000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3666000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7469000
CY2023Q4	tlis	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	3666000
CY2022Q4	tlis	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	7469000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3666000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7469000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	20400000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	29400000
CY2023	tlis	Percentage Of Net Operating Loss And Tax Credit Carryforwards Utilization Subject To Substantial Annual Limitation PercentageOfNetOperatingLossAndTaxCreditCarryforwardsUtilizationSubjectToSubstantialAnnualLimitation	0.50
CY2023	tlis	Net Operating Loss And Tax Credit Carryforwards Utilization Period NetOperatingLossAndTaxCreditCarryforwardsUtilizationPeriod	P3Y
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8973000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7244000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1365000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1729000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	10338000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8973000
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2023	tlis	Pending Income Tax Examination PendingIncomeTaxExamination	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-62007000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-113012000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1817506
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1817506
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1800447
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1800447
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-34.12
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-34.12
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-62.77
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-62.77
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30596388
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30458084
CY2023	us-gaap	Description Of Defined Contribution Pension And Other Postretirement Plans DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans	The Company has a qualified deferred compensation plan under Section 401(k) of the Internal Revenue Code of 1986, as amended (401(k) Plan).
CY2023	tlis	Defined Contribution Plan Automatic Matching Contribution Basis DefinedContributionPlanAutomaticMatchingContributionBasis	one-for-one
CY2023	tlis	Defined Contribution Plan First Automatic Matching Contribution Plan Percent DefinedContributionPlanFirstAutomaticMatchingContributionPlanPercent	0.03
CY2023	tlis	Percentage Of Employees Eligible For Dollar Automatic Matching Contribution Plan PercentageOfEmployeesEligibleForDollarAutomaticMatchingContributionPlan	0.50
CY2023	tlis	Defined Contribution Plan On Dollar Automatic Matching Contribution Plan Percent DefinedContributionPlanOnDollarAutomaticMatchingContributionPlanPercent	0.02
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.04
CY2023	tlis	Defined Contribution Plan Employer Matching Contribution Amount DefinedContributionPlanEmployerMatchingContributionAmount	600000
CY2022	tlis	Defined Contribution Plan Employer Matching Contribution Amount DefinedContributionPlanEmployerMatchingContributionAmount	900000
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
CY2023	ecd	Insider Trd Policies Proc Adopted Flag InsiderTrdPoliciesProcAdoptedFlag	true

Files In Submission

Name	View Source	Status
0000950170-24-037648-index-headers.html	Edgar Link	pending
0000950170-24-037648-index.html	Edgar Link	pending
0000950170-24-037648.txt	Edgar Link	pending
0000950170-24-037648-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlis-20231231.htm	Edgar Link	pending
tlis-20231231.xsd	Edgar Link	pending
tlis-ex10_24.htm	Edgar Link	pending
tlis-ex19_1.htm	Edgar Link	pending
tlis-ex23_1.htm	Edgar Link	pending
tlis-ex31_1.htm	Edgar Link	pending
tlis-ex31_2.htm	Edgar Link	pending
tlis-ex32_1.htm	Edgar Link	pending
tlis-ex32_2.htm	Edgar Link	pending
tlis-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TLIS
Talis Biomedical Corp Stock $tlis

2024 Q1 Form 10-K Financial Statement

#000095017024037648 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLIS Talis Biomedical Corp Stock $tlis

2024 Q1 Form 10-K Financial Statement

#000095017024037648 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLIS
Talis Biomedical Corp Stock $tlis